Sakar Healthcare (SAKAR) — Consolidated Revenue ₹7,126.82 Cr
Filing Analysis
Key Event
Sakar Healthcare Limited (SAKAR) announced audited consolidated financial results for FY2026, reporting:
The results were approved on May 12, 2026, with an unmodified auditor’s opinion. No forward guidance or material uncertainties were disclosed.
Investor Implications
Financial Snapshot
| Metric | FY2026 Value | Peer Avg. (Sector) |
|---|---|---|
| Revenue | ₹7,126.82 Cr | — |
| PAT | ₹1,102.43 Cr | — |
| EPS | ₹4.96 | — |
| P/E Ratio | 121.01 | 50.85 |
| Price to Sales (TTM) | 10.76 | Sector avg: ~5 |
| Profit Growth (YoY) | 19.17% | — |
Note: Valuation multiples are significantly above sector averages, reflecting growth expectations but increasing sensitivity to execution risks.
Takeaway
Sakar Healthcare delivered robust FY2026 performance with strong revenue and profit growth, supported by oncology expansion and new product approvals. However, its premium valuation requires sustained execution to justify current price levels.
🔍 For Deep Analysis (click below):
What is the breakdown of revenue by domestic vs. international markets for FY2026?
Based on the recent filings and investor presentations for Sakar Healthcare Limited (SAKAR), here’s the breakdown of revenue by domestic vs. international markets for FY2026:
Key Figures from FY2026
₹2,709 crores (38% of total revenue), driven largely by oncology products in the EU market .
₹4,417 crores (62% of total revenue), including both oncology and non-oncology segments .
Growth Drivers
Note: The majority of Sakar’s international revenue comes from oncology exports, particularly in Europe, while domestic sales remain strong across therapeutic areas.
Peer Comparison
Sakar’s export-focused oncology strategy differentiates it from peers, who typically derive a smaller portion of revenue from international markets.
Takeaway
Sakar Healthcare’s FY2026 revenue split shows a strong international presence in oncology, with exports making up nearly 40% of total revenue, underscoring its global expansion strategy.
🔍 For Deep Analysis (click below):
Key subsidiaries of SAKAR?
Key Subsidiaries of SAKAR
Based on the FY2026 consolidated financial results filing, here are the key subsidiaries of Sakar Healthcare Limited (SAKAR):
Subsidiaries
- Ownership: Wholly owned subsidiary
- Role: Core oncology business driver
- Contribution: Key contributor to the company's oncology revenue, which represented 38% of total FY2026 revenue (₹2,709 crores out of ₹7,126.82 crores)
- Growth: Oncology exports grew from ₹22 lakhs in Q4 FY25 to ₹30 lakhs in Q4 FY26, with management projecting ₹50–100 crores in exports over the next two years
Other Entities
> *"Other than this, the Company does not have any subsidiary/associate."*
Strategic Context
Note: The consolidated financials fully consolidate Sakar Oncology Private Limited, reflecting its integral role in the group's operations.
Takeaway
Sakar Healthcare operates primarily through its wholly owned subsidiary, Sakar Oncology Private Limited, which drives the company's oncology-focused growth strategy. No other subsidiaries or associates are reported.
How does Sakar’s oncology export growth compare to peers like Dr. Reddy’s or Sun Pharma?
Sakar vs. Peers: Oncology Export Growth Comparison
Sakar Healthcare Limited (SAKAR)
- Q4 FY26: ₹30 lakhs (up from ₹22 lakhs YoY) - FY27 Outlook: Management projects ₹50–100 crores in oncology exports over two years - Strategic Drivers:
- 12 new marketing authorizations for oncology products - Ongoing technology transfers with global partners (Zydus, Intas, Glenmark, etc.) - Bavla facility expansion potential for ₹800–1,000 crores in future oncology export revenue ### Dr. Reddy’s Laboratories (DRREDDY)
- Semaglutide approval in India - Denosumab biosimilar launch in Germany - Immutep immunotherapy collaboration ### Sun Pharmaceutical Industries Limited (SUNPHARMA)
- FY26 Results: Revenue ₹350,128 crores, net profit ₹118,093 crores with 26.2% YoY growth - Dividend: Recommended ₹5 per share final dividend for FY26 - Strategic Shift: Moving toward specialty pharmaceuticals via acquisitions rather than organic export growth ---
Key Takeaways
Peer Comparison Table (FY26 Highlights)
| Metric | Sakar (SAKAR) | Dr. Reddy’s (DRREDDY) | Sun Pharma (SUNPHARMA) |
|---|---|---|---|
| Total Revenue (₹ Cr) | 7,126.82 | 34,682.2 | 56,809.09 |
| Oncology Revenue Share | 38% (exports) | Not specified | Not specified |
| Recent Oncology Export | ₹30 lakhs (Q4 FY26) | Bosutinib launch US | Organon acquisition |
| FY27 Growth Guidance | 40% revenue growth | Not specified | Not specified |
| Key Strategic Move | Tech transfers, new approvals | US generic launches | $11.75bn Organon deal |
🔍 For Deep Analysis (click below):
How does Sakar’s oncology export growth compare to peers like Dr. Reddy’s or Sun Pharma?
Sakar vs. Dr. Reddy's vs. Sun Pharma: Oncology Export Growth Comparison
Sakar Healthcare Limited (SAKAR)
- Q4 FY26: ₹30 lakhs (up from ₹22 lakhs YoY) - FY27 Outlook: Management projects ₹50–100 crores in oncology exports over two years - Strategic Drivers:
- 12 new marketing authorizations for oncology products - Ongoing technology transfers with global partners (Zydus, Intas, Glenmark, etc.) - Bavla facility expansion potential for ₹800–1,000 crores in future oncology export revenue
Dr. Reddy's Laboratories (DRREDDY)
- Semaglutide approval in India - Denosumab biosimilar launch in Germany - Immutep immunotherapy collaboration
Sun Pharmaceutical Industries Limited (SUNPHARMA)
- FY26 Results: Revenue ₹350,128 crores, net profit ₹118,093 crores with **26.2% YoY gr
Key Takeaway: Sakar's oncology export growth is still in its early stages compared to established peers like Dr. Reddy's and Sun Pharma, but its FY27 projection of ₹50–100 crores over two years and Bavla facility potential signal strong upside potential.